Stroke · 2018 · 149 citations · 20 references
MedicineNeurologyNeurosurgeryCerebrovascular SurgeryMeta-analysisOutcomes ResearchAcute Ischemic StrokeAcute Stroke ManagementCerebral RevascularizationCerebrovascular DiseaseCerebrovascular RevascularizationStrokeAcute Ischemic Stroke InterventionAcute Ischemic Stroke ManagementAcute Ischemic Stroke TreatmentBayesian Network Meta-analysisIntracranial Large Vessel OcclusionMulticenter TrialsPost-stroke Antithrombotic TherapyPrimary Efficacy Endpoints
BACKGROUND AND PURPOSE: EmboTrap is a novel stent retriever designed to achieve rapid and substantial flow restoration in acute ischemic stroke secondary to large-vessel occlusions. Here, we evaluated EmboTrap's safety and efficacy compared with established stent retrievers. METHODS: ARISE II (Analysis of Revascularization in Ischemic Stroke With EmboTrap) was a single-arm, prospective, multicenter study, comparing the EmboTrap device to a composite performance goal criterion derived using a Bayesian meta-analysis from the pivotal SWIFT (Solitaire device) and TREVO 2 (Trevo device) trials. Patients at 11 US and 8 European sites were eligible for inclusion if they had large-vessel occlusions and moderate-to-severe neurological deficits within 8 hours of symptom onset. The primary efficacy end point was achievement of modified Thrombolysis in Cerebral Ischemia (mTICI) reperfusion scores of ≥2b within 3 EmboTrap passes as adjudicated by the core laboratory. The primary safety end point was a composite of symptomatic intracerebral hemorrhage and serious adverse device effects. Secondary end points included functional independence (modified Rankin Scale, 0-2) and all-cause mortality at 90 days. RESULTS: value, <0.0001), and mTICI 2c/3 was 65%. After all interventions, mTICI 2c/3 was achieved in 76%, and mTICI ≥2b was 92.5%. The rate of first pass (mTICI ≥2b following a single pass) was 51.5%. The primary safety end point composite rate of symptomatic intracerebral hemorrhage or serious adverse device effects was 5.3%. Functional independence and all-cause mortality at 90 days were 67% and 9%, respectively. CONCLUSIONS: The EmboTrap stent-retriever mechanical thrombectomy device demonstrated high rates of substantial reperfusion and functional independence in patients with acute ischemic stroke secondary to large-vessel occlusions. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02488915.
20
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Olvert A. Berkhemer, Puck Fransen, Debbie Beumer et al. · New England Journal of Medicine · 2014 · 6.6K citations · Full text
Medicine, Neurology, Neurosurgery +14
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
Bruce Campbell, Peter Mitchell, Timothy Kleinig et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
Jeffrey L. Saver, Mayank Goyal, Alain Bonafé et al. · New England Journal of Medicine · 2015 · 5.1K citations · Full text
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
Tudor G. Jovin, Ángel Chamorro, Erik Cobo et al. · New England Journal of Medicine · 2015 · 4.9K citations · Full text
William J. Powers, Colin P. Derdeyn, José Biller et al. · Stroke · 2015 · 2.1K citations